- Home
- KULR vs SWKH Comparison
KULR vs SWKH Comparison
Compare KULR & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KULR | SWKH |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Diversified Financial Services |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 175.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | KULR | SWKH |
|---|---|---|
| Price | $3.35 | $17.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $40.00 | $18.00 |
| AVG Volume (30 Days) | ★ 1.9M | 9.9K |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | N/A | ★ 1.85 |
| Revenue | $16,677,036.00 | ★ $40,149,000.00 |
| Revenue This Year | $27.50 | $52.93 |
| Revenue Next Year | $164.50 | N/A |
| P/E Ratio | ★ N/A | $9.39 |
| Revenue Growth | ★ 71.92 | 62.38 |
| 52 Week Low | $2.15 | $13.17 |
| 52 Week High | $43.92 | $20.49 |
Technical Indicators
Market Signals| Indicator | KULR | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 58.73 |
| Support Level | $3.70 | $16.73 |
| Resistance Level | $4.36 | $17.47 |
| Average True Range (ATR) | 0.34 | 0.32 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 52.40 | 61.29 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.